Multimodal neuroimaging study of regulating menstruation and promoting pregnancy acupuncture therapy in patients with polycystic ovary syndrome

注册号:

Registration number:

ITMCTR2200006569

最近更新日期:

Date of Last Refreshed on:

2022-09-06

注册时间:

Date of Registration:

2022-09-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

调经促孕针法对多囊卵巢综合征患者的多模态神经影像学研究

Public title:

Multimodal neuroimaging study of regulating menstruation and promoting pregnancy acupuncture therapy in patients with polycystic ovary syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针灸推拿学

Scientific title:

acupuncture and tuina

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200063421 ; ChiMCTR2200006569

申请注册联系人:

徐呈超

研究负责人:

徐呈超

Applicant:

xu chengchao

Study leader:

xu chengchao

申请注册联系人电话:

Applicant telephone:

18253129068

研究负责人电话:

Study leader's telephone:

18253129068

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18253129068@163.com

研究负责人电子邮件:

Study leader's E-mail:

18253129068@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

山东省济南市天桥区无影山中路11号

研究负责人通讯地址:

山东省济南市天桥区无影山中路11号

Applicant address:

11 Middle Wuyingshan Road, Tianqiao District, Jinan City, Shandong Province, China

Study leader's address:

11 Middle Wuyingshan Road, Tianqiao District, Jinan City, Shandong Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东省立第三医院

Applicant's institution:

Shandong Provinicial Third Hospital,Shandong University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

KYLL-2022021

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

山东省立第三医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shandong Provinicial Third Hospital,Shandong University

伦理委员会批准日期:

Date of approved by ethic committee:

2022/6/7 0:00:00

伦理委员会联系人:

张新国

Contact Name of the ethic committee:

zhang xinguo

伦理委员会联系地址:

山东省济南市天桥区无影山中路11号

Contact Address of the ethic committee:

11 Middle Wuyingshan Road, Tianqiao District, Jinan City, Shandong Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东省立第三医院

Primary sponsor:

Shandong Provinicial Third Hospital,Shandong University

研究实施负责(组长)单位地址:

山东省济南市天桥区无影山中路11号

Primary sponsor's address:

11 Middle Wuyingshan Road, Tianqiao District, Jinan City, Shandong Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

济南市

Country:

China

Province:

shandong province

City:

Jinan City

单位(医院):

山东省立第三医院

具体地址:

山东省济南市天桥区无影山中路11号

Institution
hospital:

Shandong Provinicial Third Hospital,Shandong University

Address:

11 Middle Wuyingshan Road, Tianqiao District, Jinan City, Shandong Province, China

经费或物资来源:

科研经费

Source(s) of funding:

scientific research funds

研究疾病:

多囊卵巢综合征

研究疾病代码:

Target disease:

polycystic ovarian syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

非随机对照试验

Non randomized control

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

应用rs-fMRI技术,观察调经促孕针法对PCOS的临床疗效,并采用多模态方法,从功能层面和结构层面两个角度探析针灸治疗PCOS的神经影像学机制。

Objectives of Study:

Rs-fMRI technique was used to observe the clinical efficacy of acupuncture for regulating menstruation and promoting pregnancy on PCOS, and multi-modal method was used to explore the neuroimaging mechanism of acupuncture on PCOS from the functional and structural perspectives.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

PCOS: ①稀发排卵或无排卵(临床表现为月经稀发、闭经); ②具高雄激素血症的临床和或生化特征; ③卵巢多囊样改变。 以上三条中符合两条。 健康女性: 身体状态良好、月经周期规律、卵巢功能正常、妇科彩超正常、右利手、无器质性或严重功能性疾病、无精神疾病史、无MRI禁忌症等者。 ①18-40岁女性; ②右利手; ③近1个月内未进行过针灸治疗; ④自愿参加本实验且坚持治疗,签署知情同意者。

Inclusion criteria

PCOS: ① Sparse ovulation or anovulation (clinical manifestations are sparse menstruation and amenorrhea); ② Clinical and/or biochemical features of hyperandrogenemia; ③ Polycystic changes in ovary. Two of the above three are true. Healthy women: Good physical condition, regular menstrual cycle, normal ovarian function, normal gynecological color doppler ultrasound, right-handedness, no organic or serious functional diseases, no history of mental illness, no MRI contraindications, etc. ① Women aged 18-40; ② Right hand; ③ No acupuncture treatment in the past 1 month; ④ Those who voluntarily participated in the experiment and insisted on treatment and signed informed consent.

排除标准:

①合并其他内分泌系统疾病,包括:先天性肾上腺皮质增生、肾上腺肿瘤、库欣氏综合征、卵巢或肾上腺分泌雄激素的肿瘤、垂体泌乳素瘤、糖尿病、甲状腺疾病等; ②合并严重原发病,如心脑血管、呼吸系统、肝脏、肾脏、消化、血液系统、免疫系统以及神经精神系统等的严重疾病; ③血栓病史或患有易栓症; ④近3个月内有物质滥用:包括严重酗酒、吸烟(每天1包及以上)、吸毒; ⑤近3个月内服用定坤丹或达英-35或其他口服避孕药及性激素药物; ⑥孕妇和哺乳期妇女,以及产后1年内妇女; ⑦体内有金属、有幽闭恐惧症等磁共振禁忌症。

Exclusion criteria:

① Complicated with other endocrine system diseases, including congenital adrenal hyperplasia, adrenal tumor, Cushing's syndrome, ovarian or adrenal tumor secreting androgen, pituitary prolactinoma, diabetes mellitus, thyroid disease, etc. ② Complicated with serious primary diseases, such as serious diseases of cardiovascular and cerebrovascular system, respiratory system, liver, kidney, digestive system, blood system, immune system and neuropsychiatric system; (3) history of thrombosis or thromboembolism; (4) Substance abuse in the past 3 months, including serious alcohol abuse, smoking (1 pack or more per day), drug abuse; ⑤ Taking dingkundan or Dayin-35 or other oral contraceptives and sex hormone drugs within the last 3 months; ⑥ Pregnant and lactating women, and women within 1 year after delivery; There are metal in the body, claustrophobia and other mri contraindications.

研究实施时间:

Study execute time:

From 2022-08-01

To      2024-07-31

征募观察对象时间:

Recruiting time:

From 2022-08-24

To      2023-07-31

干预措施:

Interventions:

组别:

健康人组

样本量:

20

Group:

Healthy people group

Sample size:

干预措施:

不干预

干预措施代码:

Intervention:

nonintervention

Intervention code:

组别:

PCOS组

样本量:

20

Group:

PCOS group

Sample size:

干预措施:

针灸治疗

干预措施代码:

Intervention:

acupuncture

Intervention code:

样本总量 Total sample size : 40

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

shandong province

City:

单位(医院):

山东省立第三医院

单位级别:

省级医院

Institution/hospital:

Shandong Provinicial Third Hospital,Shandong University

Level of the institution:

Provincial hospital

测量指标:

Outcomes:

指标中文名:

Ferriman-Gallway毛发评分标准

指标类型:

次要指标

Outcome:

Ferriman-gallway Hair Rating Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经影像学指标

指标类型:

主要指标

Outcome:

Neuroimaging index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

月经情况

指标类型:

次要指标

Outcome:

Menstruation situation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评量表

指标类型:

次要指标

Outcome:

Self-rating Depression Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

LH/FSH

指标类型:

主要指标

Outcome:

LH/FSH

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

痊疮综合分级系统表

指标类型:

次要指标

Outcome:

GAGS table

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

self-rating anxiety scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 40
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

无随机

Randomization Procedure (please state who generates the random number sequence and by what method):

No random

盲法:

Blinding:

no

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

联系通讯作者

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact corresponding author

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above